Astellas Gene Therapies
在场
Astellas Gene Therapies 的所有者是 Astellas Pharma.
是其中之一......
Astellas Pharma 是一家在股票代码 4503 (JP) 下上市的公司。
Astellas Pharma 在 11 个国家有直接业务。Astellas Pharma 拥有 12家子公司，其中包括 Astellas Farma Brasil、Astellas Gene Therapies 和 Astellas Netherlands。
他们在：
涉及Astellas Pharma的并购和融资。
- Astellas Pharma has announced the acquisition of Iveric Bio (公布2023七月12号).
- Astellas Pharma has announced the acquisition of Iveric Bio (公布2023五月3号).
高管
查看带有其 5 名主要高管的组织结构图
Astellas Gene Therapies 搜索最多的简介
- Jason Schwartz, Vice President and Global Head, Medical Affairs, O...
- David Smethurst, Vice President and Head of Regulatory Affairs
- Morten Sogaard, Senior Vice President, Gene Therapy Research & Tec...
高管在Astellas Pharma变化
- Rika HirotaRika Hirota 将于20246月20作为 Director 加入公司 (新闻发布的2024四月26号).
- Tomoko AramakiTomoko Aramaki 将于20246月20作为 Director 加入公司 (新闻发布的2024四月26号).
创建提醒
跟踪 Astellas Gene Therapies 的高管变动
生物技术
Astellas Pharma 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Astellas Gene Therapies 的最新新闻稿
- Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications - Astellas Gene Therapies
- Astellas Completes Acquisition of Audentes Therapeutics | Audentes Therapeutics
- Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics | Audentes Therapeutics
- Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update | Audentes Therapeutics
- Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019 | Audentes Therapeutics
- Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society | Audentes Therapeutics
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Audentes Therapeutics
- Audentes Therapeutics to Participate in Upcoming Investor Conferences | Audentes Therapeutics
- Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM) | Audentes Therapeut
- Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Audentes Therapeutics
- View more press releases Close
通过电子邮件
